Click to view the original PDF
The research report was released on August 31 to maintain the Shanghai Haohai Biological Technology Co.Ltd(688366) buy rating. Tianfeng Securities Co.Ltd(601162) predicts that the net profit attributable to the parent company in Shanghai Haohai Biological Technology Co.Ltd(688366) 2021 will be 498 million yuan, with a year-on-year increase of 116.34%.
Main financial indicators and valuation
2021E
2022E
2023E
Total operating revenue (100 million yuan) 2.0025 billion yuan four thousand seven hundred and thirty-two point nine six
Net profit attributable to parent company (RMB 100 million) 498.6 million six hundred and fifty-eight point eight one
Earnings per share (yuan) 2.823 seven hundred and seventy-four point nine nine
Net assets per share (yuan) 33.0735 six thousand four hundred and thirty-nine point zero seven
Price earnings ratio (PE) 614635
Price to book ratio (PB) 5.234 eight hundred and fifty-four point four three
Return on net assets (%) 8.5210 five thousand seven hundred and twelve point seven seven
Note: the data is obtained from the text of the research report.
Shanghai Haohai Biological Technology Co.Ltd(688366) it has attracted the attention of 9 research reports of securities companies in recent month. According to the reverse order of the release date of the research report, the latest research report data of the five securities companies are shown in the table below:
Research report date
Organization abbreviation
Target price
This rating
details
Comments on August 31, 2021 Tianfeng Securities Co.Ltd(601162) - buying the semi annual report: the coverage of ophthalmic industry chain continues to expand, and the growth of medical and American business accelerates
2021-08-30 Founder Securities Co.Ltd(601901) - it is recommended that all businesses achieve rapid growth, R & D + M & a continue to expand ophthalmology and medical beauty product lines
2021-08-30 Gf Securities Co.Ltd(000776) 222 purchase of "ophthalmology + medical beauty" two wheel drive, contributing to the rapid growth of performance
2021-08-29 Sinolink Securities Co.Ltd(600109) - the buying performance is beautiful, and the new products of Ophthalmology and medical beauty promote strong growth
2021-08-29 Soochow Securities Co.Ltd(601555) - buy comment on 2021 China Daily: pay equal attention to self-research and investment, and the ophthalmology will fly together
Disclaimer: This article is based on big data production and is for reference only. It does not constitute any investment suggestions. Therefore, the operator shall bear the operational risk.
